Fmr LLC Bolt Biotherapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 86,613 shares of BOLT stock, worth $52,833. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,613

Previous 78,899 9.78%

Holding current value

$52,833

Previous $110,000 41.82%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.73 - $1.5 $5,631 - $11,571	7,714 Added 9.78%	86,613 $64,000
Q1 2024 May 13, 2024	SELL	$1.01 - $1.4 $296 - $411	-294 Reduced 0.37%	78,899 $110,000
Q4 2023 Feb 13, 2024	SELL	$0.85 - $1.12 $2 - $3	-3 Reduced -0.0%	79,193 $88,000
Q2 2023 Aug 11, 2023	BUY	$1.27 - $1.95 $969 - $1,487	763 Added 0.97%	79,196 $101,000
Q1 2023 May 11, 2023	SELL	$1.29 - $1.66 $7 - $9	-6 Reduced 0.01%	78,433 $109,000
Q4 2022 Feb 13, 2023	SELL	$1.26 - $1.51 $1,040 - $1,247	-826 Reduced 1.04%	78,439 $101,000
Q3 2022 Nov 10, 2022	SELL	$1.48 - $2.61 $735 - $1,297	-497 Reduced 0.62%	79,265 $117,000
Q2 2022 Aug 12, 2022	BUY	$1.41 - $2.91 $184 - $381	131 Added 0.16%	79,762 $162,000
Q1 2022 May 13, 2022	SELL	$2.74 - $4.82 $3.88 Million - $6.82 Million	-1,415,324 Reduced 94.67%	79,631 $218,000
Q4 2021 Feb 14, 2022	SELL	$4.19 - $13.97 $5.53 Million - $18.4 Million	-1,319,428 Reduced 46.88%	1,494,955 $7.33 Million
Q3 2021 Nov 15, 2021	SELL	$11.15 - $18.6 $248,678 - $414,835	-22,303 Reduced 0.79%	2,814,383 $35.6 Million
Q2 2021 Aug 13, 2021	BUY	$15.4 - $31.46 $43.7 Million - $89.2 Million	2,836,686 New	2,836,686 $43.9 Million

Others Institutions Holding BOLT

# of Institutions

Shares Held

23M

Call Options Held

Put Options Held

View Full List

About Bolt Biotherapeutics, Inc.

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $23M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

More about BOLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account